Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Register now for the “Q4 Earnings Season Wrap-Up.”
Join stock market expert Marc Chaikin (the creator of Chaikin Money Flow) and Explosive Options’ Bob Lang for a special earnings season wrap-up.

You’ll find out the biggest takeaways from recent earnings results and what it means for the market—and YOUR money. 

Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 360,757
  • Shares Outstanding, K 108,994
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,200 K
  • 36-Month Beta 2.14
  • Price/Sales 13.50
  • Price/Cash Flow N/A
  • Price/Book 4.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.08
  • Number of Estimates 4
  • High Estimate -0.07
  • Low Estimate -0.08
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.18 +0.79%
on 02/19/19
3.88 -17.40%
on 01/24/19
-0.54 (-14.30%)
since 01/18/19
3-Month
2.23 +43.72%
on 12/21/18
4.14 -22.49%
on 01/16/19
-0.40 (-11.22%)
since 11/21/18
52-Week
1.63 +96.63%
on 03/05/18
7.21 -55.55%
on 07/09/18
+1.53 (+91.92%)
since 02/21/18

Most Recent Stories

More News
ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March 7, 2019. The Company will...

ARQL : 3.22 (-2.72%)
ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Brian Schwartz, M.D., Chief Medical Officer and Head of Research and Development, of ArQule will...

ARQL : 3.22 (-2.72%)
Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA)

--83% disease control rate

ARQL : 3.22 (-2.72%)
4 Pharma Stocks Heating Up On Wednesday (12/26/18)

CORAL GABLES, FL/ ACCESSWIRE / December 26,2018 / The, like other healthcare related fields, is predicated on the idea that we can do better, in terms of made available to consumers as well as medical...

AVEO : 0.63 (+1.61%)
ARQL : 3.22 (-2.72%)
AMRN : 17.29 (+0.52%)
Biotech News Driving These Companies

HENDERSON, NV / ACCESSWIRE / December 26, 2018 / The news isn't all gloom and doom, the biotech companies highlighted below have all released positive news recently.

ARQL : 3.22 (-2.72%)
ADIL : 4.00 (+18.69%)
ENDV : 0.0228 (+3.64%)
ACOR : 13.41 (+2.37%)
EARS : 0.36 (unch)
Options Traders Expect Huge Moves in ArQule (ARQL) Stock

ArQule (ARQL) needs investors to pay close attention to the stock based on moves in the options market lately.

ARQL : 3.22 (-2.72%)
ArQule Added to the NASDAQ Biotechnology Index

ArQule, Inc. (Nasdaq: ARQL) today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday,...

ARQL : 3.22 (-2.72%)
ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies

ArQule, Inc. (Nasdaq: ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from the company's Phase 1 dose escalation study...

ARQL : 3.22 (-2.72%)
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting

ArQule, Inc. (Nasdaq:ARQL) today announced that it will present clinical data on the company's BTK inhibitor, ARQ 531, in a poster presentation at the 60th American Society of Hematology...

ARQL : 3.22 (-2.72%)
ArQule Presents Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium

ArQule, Inc. (Nasdaq: ARQL) today announced the presentation of clinical and preclinical data on ARQ 751 in three poster presentations at the 30th EORTC/AACR/NCI Symposium held from November...

ARQL : 3.22 (-2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ARQL with:

Business Summary

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage...

See More

Key Turning Points

2nd Resistance Point 3.50
1st Resistance Point 3.40
Last Price 3.22
1st Support Level 3.20
2nd Support Level 3.10

See More

52-Week High 7.21
Fibonacci 61.8% 5.08
Fibonacci 50% 4.42
Fibonacci 38.2% 3.76
Last Price 3.22
52-Week Low 1.63

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar